Portal de investigación
ESTUDIO OBSERVACIONAL POST-AUTORIZACION DE SEGURIDAD DE FEIBA (COMPLEJO COAGULANTE ANTI-INHIBIDOR DEL FACTOR VIII) ESTUDIO DE COHORTES, OBSERVACIONAL, ABIERTO, NO CONTROLADO, DE FEIBA EN PACIENTES HEMOFILICOS CON INHIBIDOR
Datos básicos
- Código:
- PASS-EU-006
- Protocolo:
- PASS-EU-006
- EUDRACT:
- NO PROCEDE
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Challenges, questions and opportunities with regard to the new relationship between clinical practice and the haemostasis laboratory: the path towards personalized medicine.
Article. 10.1097/MBC.0000000000001091. 2021
Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.
Fischer K; (...); Königs C
Article. 10.1182/bloodadvances.2023011442. 2024
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Efficacy and safety evaluation of Fanhdi ® , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.
Jimenez-Yuste, Victor; (...); Paez, Antonio
Letter. 10.1111/hae.14453. 2022
Emicizumab-induced photosensitivity.
Asensi Canto, Pedro; (...); Haya Guaita, Saturnino
Article. 10.1055/s-0042-1749092. 2022
Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions
Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta
Meeting Abstract. 2024
IMPACT OF INITIATION OF PROPHYLAXIS, SYNOVITIS AND FUNCTIONALITY ON JOINT HEALTH IN PATIENTS WITH HEMOPHILIA
Chimeno, A.; (...); Bonanad Boix, S.
Meeting Abstract. 2023
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Management of acquired hemophilia A: results from the Spanish registry.
Mingot-Castellano ME; (...); Marco P
Article. 10.1182/bloodadvances.2021004626. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
Megias-Vericat, J. E.; (...); Poveda Andres, J. L.
Article. 10.1016/j.thromres.2022.06.001. 2022
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.
Megias-Vericata, J. E.; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2023.11.023. 2023
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.
Ettingshausen CE; (...); Windyga J
Article. 10.1177/20406207231184323. 2023
The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
Gresele, P; (...); BAT-VAL Study Investigators
Article. 10.1111/jth.15263. 2021
Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project
Perez-Rodriguez, Almudena; (...); Lopez-Fernandez, Maria Fernanda
Article. 10.1111/hae.14405. 2021